Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa

Clinical Infectious Diseases

Volumn 53, Issue 4, 2011, Pages 369-372

  Jacobson, Karen R ^a   Theron, Danie ^b   Victor, Thomas C ^c   Streicher, Elizabeth M ^c   Warren, Robin M ^c   Murray, Megan B ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Brewelskloof Hospital   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG DOSE INCREASE; DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AFRICA; SPUTUM CULTURE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79961212199     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir406     Document Type: Article

References (12)

1. World Health Organization (WHO). Global tuberculosis control 2010. Available at: http://www.who.int/tb/publications/global-report/2010/en/index. html. Accessed 6 December 2010.
2. Boehme C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
3. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363:474-81. (Pubitemid 38210067)
4. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:1-15.
5. Bang D, Andersen PH, Andersen AB, Thomsen Vø. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission, and treatment outcome. J Infect 2010; 60:452-7.
6. Cattamanchi A, Dantes RB, Metcalfe JZ, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009; 48:179-85.
7. Warren RM, Streicher EM, Gey van Pittius NC, et al. The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis 2009; 89:199-202.
8. Health Department of South Africa. South African National Tuberculosis Management Guidelines, 2008. Available at: http://www.sasohn.org.za/images/ TBGUIDELINES2008SFINALFORPRINTINGMARCH09.pdf. Accessed 20 December 2010.
9. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375:1798-807.
10. English R. Boland/Overberg Region Annual Health Status Report, 2007/8. Worcester, South Africa: Information Management Office. Available at: http://www.capegateway.gov.za/Text/2009/12/boland-overberg-region-07-08.pdf. Accessed 10 December 2010.
11. Ors F, Deniz O, Bozlar U, et al. High-resolution CT findings in patients with pulmonary tuberculosis: correlation with the degree of smear positivity. J Thorac Imaging 2007; 22:154-9. (Pubitemid 46868286)
12. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.